TOP 2301: Neoadjuvant Chemo for NSCLC

NCT06385262 · clinicaltrials.gov ↗

PHASE2

Phase

SUSPENDED

Status

126

Enrollment

OTHER

Sponsor class

Stopped Protocol is currently undergoing study design revisions and will re-open after amendment is IRB approved

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG: Alirocumab
DRUG: Cemiplimab
DRUG: Chemotherapy

Sponsor

Duke University

Collaborators

[object Object]